HLA Typing Market

Growing need for organ transplants is driving the market growth

Market CAGR for HLA Typing is being driven by the rising number of organ transplants. Human Leukocyte Antigen typing, or HLA typing, is a crucial procedure in organ and tissue transplantation that establishes the compatibility of the recipient and donor. The proteins called HLA molecules, which are present on the surface of cells, help the immune system distinguish between self and non-self-cells. A close match between the recipient's and donor's HLA types lowers the possibility of transplant rejection.

Additionally, the demand for HLA typing to reduce the risk of graft rejection and immunosuppressant has increased due to the rising  burden of chronic diseases, including acute and chronic hepatitis, coronary artery disease, end-stage renal disease, chronic kidney disease, and chronic renal disease among people of all ages. Using DNA-based molecular diagnostic techniques, HLA typing looks for each individual's unique set of HLA antigens. HLA matching lowers the risk of graft-versus-host disease and increases the production of new, healthy blood cells. Over the course of the projected period, this is anticipated to fuel market expansion.

Furthermore, throughout the course of the forecast period, rising demand for organ transplants due to an increase in end-stage diseases among the elderly population is anticipated to drive market expansion.

Rising organ transplant demand brought on by an increase in organ failure instances as a result of unhealthy lifestyles, binge drinking, and drug abuse is anticipated to further propel market revenue growth. The HLA typing for the transplant market is strongly impacted by the rising demand for organ transplants. Investments in cutting-edge HLA typing technology have been fueled by the need for exact HLA matching to increase transplant success rates. Comprehensive HLA profiling can be achieved by the use of high-throughput sequencing and other molecular approaches.

High-throughput simultaneous screening of numerous genes is made possible by next-generation sequencing (NGS) technologies, which also dramatically lower consumable costs. However, the entire sequencing procedure, from sample preparation to data archiving, is usually expensive and time-consuming.

For instance, the number of kidney, liver, and heart transplants that occurred in the United States in 2021 was 90,483, 11,891, 3,502, and 24,670, 9,236, and 3,817, respectively, according to organdonor.gov, which was last updated in March 2022. Due to the enormous volume of organ transplants performed in hospitals, HLA typing tests will consequently be used more frequently, which will fuel the expansion of this market. Thus, result in driving the HLA Typing market revenue.

The increasing incidence of genetic disorders globally drives the Global HLA Typing Market Industry. As more individuals are diagnosed with conditions such as autoimmune diseases and cancers, the demand for accurate HLA typing becomes crucial for effective treatment and management. For instance, the prevalence of conditions like Type 1 diabetes and rheumatoid arthritis has prompted healthcare providers to utilize HLA typing for better patient stratification. This trend is expected to contribute to the market's growth, with projections indicating that the market will reach 1.79 USD Billion in 2024, reflecting a growing awareness of genetic testing.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American HLA Typing market area will rule this market, owing to an increase in the number of organ transplant procedures performed, and the strong presence of important players in the area will boost market growth in this region.

Further, the major countries investigated in the market report are the US, Germany, France, the UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil.

Figure 2:  HLA TYPING MARKET SHARE BY REGION 2023 (USD Billion)

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Europe HLA Typing market has the second-largest portion of the market due to the increased efficiency, speed, and accuracy of HLA typing testing. Further, the German HLA Typing market had the biggest market share, and the UK HLA Typing market was the European market with the quickest rate of growth.

The Asia-Pacific HLA Typing Market is anticipated to expand between 2024 and 2032 at the quickest CAGR. This is due to the improved infrastructure of healthcare facilities and thoughtfully crafted reimbursement policies. Moreover, China’s HLA Typing market had the biggest market share, and the Indian HLA Typing market was the Asia-Pacific market with the quickest rate of growth.

Leading market players are putting a lot of money into R&D to expand their product lines, which will help the market for weight reduction products grow. Additionally, market players are engaging in a range of calculated initiatives to increase their worldwide presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. To grow and endure in an increasingly cutthroat and dynamic market, HLA Typing industry must provide reasonably priced goods.

Manufacturing locally is one of the primary business techniques used by manufacturers to cut operational costs in the  HLA Typing industry to help customers and expand the market segment. In recent years, the HLA Typing industry has provided some of the biggest benefits to medicine. Major players in the HLA Typing market, including Bio-Rad Laboratories, Inc (US), F Hoffmann-La Roche Ltd (Switzerland), QIAGEN V (Netherlands), Thermo Fisher Scientific Inc. (US), and bioMérieux SA (France), are engaging in research and development activities in an effort to boost market demand.

American company Bio-Rad Laboratories, Inc. develops and produces specialized technology products for the clinical diagnostics and life science research industries. The company was founded in Berkeley, California, in 1952 by married University of California, Berkeley students David and Alice Schwartz. The headquarters of the multinational corporation Bio-Rad are in Hercules, California. In March 2023, Bio-Rad was given the iQ-Check kits that the company sells, approved by AOAC International and AFNOR for use with the CFX Opus Deep well Real-time PCR System.

Known by most as Roche, F. Hoffmann-La Roche AG is a multinational healthcare corporation based in Switzerland that operates in two divisions, diagnostics and pharmaceuticals. Shares of Roche Holding AG, its parent firm, are traded in the SIX Swiss exchanges. The company's Basel headquarters are situated there. Based on revenue, Roche ranks as the fifth-biggest pharmaceutical corporation ly. In August 2022, Roche created a brand-new computerized Light Cycler technology to assist in identifying cancer in patients.